organization · Reporting owner
ACC International Holdings Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Member of 10% owner group | July 09, 2020 | July 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date July 09, 2020 · Filed July 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,053 |
Ending reported balance
After 2020-07-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2020-07-09 · Sale · Disposed 3,500 · Balance 135,306 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 2 · 2020-07-10 · Sale · Disposed 2,000 · Balance 133,306 Row 3 · 2020-07-13 · Sale · Disposed 40,000 · Balance 93,306 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 4 · 2020-07-15 · Sale · Disposed 18,430 · Balance 74,876 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 5 · 2020-07-16 · Sale · Disposed 7,823 · Balance 67,053 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2020 Filed Jul 16, 2020 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | SaleCommon Stock | 7,823 | $13.47 | $105,350.78 |
DisclosureSEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 5 ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,053 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | SaleCommon Stock | 18,430 | $13.12 | $241,714.98 |
DisclosureSEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 4 ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,876 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | SaleCommon Stock | 40,000 | $13.52 | $540,952.00 |
DisclosureSEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 3 ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,306 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2020 Filed Jul 16, 2020 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | SaleCommon Stock | 2,000 | $13.35 | $26,700.00 |
DisclosureSEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 2 ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,306 Read SEC document |
| July 09, 2020 Filed Jul 16, 2020 21:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | SaleCommon Stock | 3,500 | $13.13 | $45,938.55 |
DisclosureSEC source: 0001104659-20-084119 · tm2024939d1_4.xml · nonDerivative · entry 1 ACC International Holdings Ltd. · CIK 0001521843 · Member of 10% owner group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,306 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.